Skip to content

Medical emergency? What to do

US FDA issues alert on Abbott antibiotic

3-RXPublished December 12, 20052 min read

Key points

  • U.S. regulators alerted the public on Friday to a study showing a higher death rate among heart disease patients one year after taking the Abbott Laboratories Inc. antibiotic Biaxin, as part of an effort to release early information about potential safety concerns.
  • The study, published Thursday in the British Medical Journal, evaluated data from about 4,373 Danish heart disease patients who took Biaxin (clarithromycin) or a placebo for 14 days.
  • The scientists said the result was surprising and that the long-term safety of Biaxin should be further examined.
  • "A mechanism by which two weeks of clarithromycin could cause increased mortality measured after one year or longer is not clear," the FDA notice said.

U.S. regulators alerted the public on Friday to a study showing a higher death rate among heart disease patients one year after taking the Abbott Laboratories Inc. antibiotic Biaxin, as part of an effort to release early information about potential safety concerns.

Officials have not reached a final conclusion about the information, the notice on the Food and Drug Administration Web site said. Abbott described the results as "a random finding" that contrasted with decades of other research.

The study, published Thursday in the British Medical Journal, evaluated data from about 4,373 Danish heart disease patients who took Biaxin (clarithromycin) or a placebo for 14 days. Patients ranged in age from 18 to 85.

Researchers said 9.8 percent of Biaxin patients died within three years of treatment, compared with 7.8 percent of people who got a placebo. There were no differences in the death rates until a year following therapy.

The scientists said the result was surprising and that the long-term safety of Biaxin should be further examined.

The FDA said it was not recommending any changes in use of the drug based on the finding. Previous studies of Biaxin as well as similar drugs have not detected any increase in deaths.

"A mechanism by which two weeks of clarithromycin could cause increased mortality measured after one year or longer is not clear," the FDA notice said.

The agency described the alert as a preliminary analysis. "FDA is considering, but has not reached a final conclusion about, this information," it said.

FDA spokeswoman Laura Alvey said the agency issued the alert "in the spirit of full disclosure."

After criticism over their handling of drug safety controversies, FDA officials promised earlier this year they would release more information about potential risks.

Abbott spokesman Brian Kyhos said the Danish findings were "at odds with 50 years of data and patient experience" with macrolides, the family of antibiotics that includes Biaxin, which has been sold for 15 years.

"We believe the results are a random finding," he said.

Kyhos said there was no evidence Biaxin could permanently damage the heart. The drug stays in the body for only 36 hours.

"It is important to be careful not to create undue alarm for patients," he said.

The Biaxin alert was posted on the FDA Web site at http://www.fda.gov/cder/drug/infopage/clarithromycin/default.htm

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Experimental drug shrinks cancer tumors

An experimental cancer drug successfully shrank tumors in patients with different kinds of cancer, including typically hard-to-treat lung cancers, according to a new study. Oncologists said the research was…

4 min read

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.